Phase 3 trial to assess M72/AS01E-4 Mycobacterium tuberculosis (TB) vaccine

£12.6M GBP

Funder	Wellcome Trust
Recipient Organization	Bill & Melinda Gates Foundation
Country	United Kingdom
Start Date	Jan 13, 2023
End Date	Jan 12, 2033
Duration	3,652 days
Number of Grantees	1
Roles	Award Holder
Data Source	Europe PMC
Grant ID	`227209`

Grant Description

A Phase 3, randomized, observer-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0-,1-month schedule to adolescents and adults.